Phaseline

Targets › TRPA1

TRPA1 (Transient receptor potential cation channel subfamily A member 1): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 4; Respiratory, Other; next expected readout Feb 2027.

Ligand-activated Ca(2+)-permeable, nonselective cation channel involved in pain detection and possibly also in cold perception, oxygen concentration perception, cough, itch, and inner ear function. Has a relatively high Ca(2+) selectivity, with a preference for divalent over monovalent cations (Ca(2+) > Ba(2+) > Mg(2+) > NH4(+) > Li(+) > K(+)), the influx of cation into the cytoplasm leads to membrane depolarization. (UniProt, O75762)

Open in Phaseline: the race on TRPA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sport and Spine Rehab Clinical Research FoundationMenthol
Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener
TRPM8, TRPA1Phase 4Chronic Low Back Pain–
Region SkaneMenthol
Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener
TRPM8, TRPA1Phase 2Interstitial Lung Disease (ILD); AsthmaFeb 2027

Conditions

Interstitial Lung Disease (ILD) (1) Asthma (1) Chronic Low Back Pain (1)

Modalities

small molecule (2)

Companies

Region Skane (1) Sport and Spine Rehab Clinical Research Foundation (1)

Related targets

TRPM8 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.